Moleculin Biotech, Inc. (MBRX)
MBRXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$8.66
+0.0450 (+0.52%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $9.09m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.23 to $253.05
- Average volume
- 46.6k
- Previous close
- $8.62
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $50.00, +477.4% from here
Earnings
next estimate $-9.90Next report Nov 12, 2026
Mar 2026
-46.8%
Jun 2026
+9.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$5.91m | -$7.53m | -$7.87m | -$7.56m |
| Net income | -$25.40m | $15.55m | -$12.85m | -$7.63m |
News
8 latest- Moleculin Biotech, Inc. Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingFintel · 5 days ago
- Moleculin Completes Dosing In Part A Of Pivotal MIRACLE Trial; Data Readout Expected In Q1 2027 RTTNews · Oct 30, 2026
- Moleculin Biotech Consensus Price Target Increased by 1,900% to $244.80Fintel · Oct 23, 2026
- Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40% RTTNews · Oct 20, 2026
- Moleculin Biotech To Effect 1-for-20 Reverse Stock Split RTTNews · Oct 16, 2026
- Moleculin Completes Part A Enrollment In Phase 2/3 MIRACLE Trial For Relapsed AML RTTNews · Sep 29, 2026
- Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data RTTNews · Sep 28, 2026
- Moleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis RTTNews · Sep 28, 2026
The company
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company is conducting the MIRACLE ( M olecul i n R /R AML A nnAraC Cl inical E valuation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as 'Ara-C'), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- moleculin.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.